argenex (NASDAQ:ARGX) Issues Quarterly Earnings Results

argenex (NASDAQ:ARGX) announced its quarterly earnings results on Friday. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36, Zacks reports. The business had revenue of $1.75 billion during the quarter. argenex had a net margin of 32.19% and a return on equity of 43.59%.

argenex Stock Performance

Shares of argenex stock traded down $6.03 during midday trading on Friday, reaching $869.73. 97,088 shares of the company’s stock traded hands, compared to its average volume of 351,782. The stock has a 50 day moving average of $956.17 and a 200-day moving average of $885.45. argenex has a 12 month low of $661.85 and a 12 month high of $1,072.75. The company has a market cap of $54.70 billion, a PE ratio of 33.42, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Truist Financial boosted their price objective on shares of argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of argenex in a research note on Friday, October 9th. Jefferies Financial Group reiterated a “buy” rating on shares of argenex in a report on Monday, September 14th. Citizens Jmp raised their target price on argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,145.53.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.